Advanced search
Publication Cover
Postgraduate Medicine Volume 134, 2022 - Issue 1
Submit an article Journal homepage
56,020
Views
47
CrossRef citations to date
0
Altmetric
Clinical Features - Commentary

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Sean Whartona York University, McMaster University and Wharton Weight Management Clinic, Toronto, ON, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0111-1530
ORCID Icon,
Melanie Daviesb Diabetes Research Centre, University of Leicester, Leicester, UK;c NIHR Leicester Biomedical Research Centre, Leicester, UKORCID Iconhttps://orcid.org/0000-0002-9987-9371
ORCID Icon,
Dror Dickerd Internal Medicine Department & Obesity Clinic, Hasharon Hospital-Rabin Medical Center, Petach-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelORCID Iconhttps://orcid.org/0000-0001-8546-6245
ORCID Icon,
Ildiko Lingvaye Departments of Internal Medicine/Endocrinology and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USAORCID Iconhttps://orcid.org/0000-0001-7006-7401
ORCID Icon,
Ofri Mosenzonf DiabetesUnit, Department of Endocrinology and Metabolism, Hadassah Medical Center; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, IsraelORCID Iconhttps://orcid.org/0000-0002-5702-7584
ORCID Icon,
Domenica M. Rubinog Washington Center for Weight Management and Research, Arlington, VA, USAORCID Iconhttps://orcid.org/0000-0002-3072-2819
ORCID Icon &
Sue D. Pedersenh C-ENDO Diabetes & Endocrinology Clinic Calgary, Calgary, AB, CanadaORCID Iconhttps://orcid.org/0000-0002-4355-1764
ORCID Icon show all
Pages 14-19 | Received 08 Jul 2021, Accepted 27 Oct 2021, Published online: 29 Nov 2021

Citations (47)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

António Cabral Lopes, Fátima Roque, Olga Lourenço, Maria Teresa Herdeiro & Manuel Morgado. (2023) Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database. Expert Opinion on Drug Safety 22:6, pages 455-461.
Read now
Juan Pablo Frías. (2023) An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program. Expert Review of Endocrinology & Metabolism 18:2, pages 111-130.
Read now
Janine V. Kyrillos, Neil S. Skolnik, Bhasha Mukhopadhyay & Nicholas Pennings. (2022) Integrating semaglutide into obesity management – a primary care perspective. Postgraduate Medicine 134:sup1, pages 37-49.
Read now
Janine V. Kyrillos, Patrick M. O’Neil & Sean Wharton. (2022) Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. Postgraduate Medicine 134:sup1, pages 1-4.
Read now
Anastassia Amaro, Danny Sugimoto & Sean Wharton. (2022) Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate Medicine 134:sup1, pages 5-17.
Read now
David C. W. Lau, Rachel L Batterham & Carel W. le Roux. (2022) Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Review of Clinical Pharmacology 15:3, pages 251-268.
Read now

Articles from other publishers (41)

Louis J. Aronne. (2024) Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity—Reply. JAMA.
Crossref
Sarah Casella & Katelyn Galli. (2023) Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists?. Journal of Pharmacy Technology 40:2, pages 108-111.
Crossref
Jana G. Hashash, Christopher C. Thompson & Andrew Y. Wang. (2024) AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication. Clinical Gastroenterology and Hepatology 22:4, pages 705-707.
Crossref
E. D. Bulgakova, E. V. Shrayner, A. I. Khavkin, G. I. Lifshits, K. M. Nikolaychuk & M. Yu. Denisov. (2024) The relationship between gastroesophageal pathogenic reflux and metabolic syndrome. Experimental and Clinical Gastroenterology:2, pages 131-140.
Crossref
Manal F. Abdelmalek, Stephen A. Harrison & Arun J. Sanyal. (2024) The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis. Diabetes, Obesity and Metabolism.
Crossref
Bela Kolars, Ivana Minakovic, Beata Grabovac, Dejan Zivanovic & Vesna Mijatovic Jovin. (2024) Treatment adherence and the contemporary approach to treating type 2 diabetes mellitus. Biomedical Papers.
Crossref
Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Timothy Rolph, Andrew Cheng & Kitty Yale. (2024) Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clinical Gastroenterology and Hepatology.
Crossref
Justin Wan, Caesar Ferrari & Micheal Tadros. (2024) GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment. Gastroenterology Insights 15:1, pages 191-212.
Crossref
Armando Ferrera, Giovanna Gallo & Massimo Volpe. (2024) Obesity and Overweight: The “Elephant in the Room” That We can No Longer Ignore: Time to SELECT Treatments. High Blood Pressure & Cardiovascular Prevention 31:1, pages 3-6.
Crossref
Klara R. Klein, Kim K.B. Clemmensen, Edwin Fong, Søren Olsen, Trine Abrahamsen & Ildiko Lingvay. (2024) Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care 47:2, pages 280-284.
Crossref
Hiren Patel, Kamlesh Khunti, Helena W. Rodbard, Harpreet S. Bajaj, Ross Bray, Zbigniew Kindracki & Ángel Rodríguez. (2023) Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials . Diabetes, Obesity and Metabolism 26:2, pages 473-481.
Crossref
Ana Cristina García-Ulloa, Salvador Jaime-Casas, Johanna Rosado-Lozoya, Nancy H. Serrano-Pérez, Diana Hernández-Juárez, José Luis Cárdenas-Fragoso, Luis Eduardo Briones-García, Rodolfo Jiménez-Soto, Carlos García-Padilla, Juan García-Lara, Carlos A. Aguilar-Salinas & Sergio Hernández-Jiménez. (2024) De-escalating treatment indications for patients who achieve metabolic goals. Diabetes Research and Clinical Practice 208, pages 111096.
Crossref
Byung-Wan Lee, Young Min Cho, Sin Gon Kim, Seung-Hyun Ko, Soo Lim, Amine Dahaoui, Jin Sook Jeong, Hyo Jin Lim & Jae Myung Yu. (2024) Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes. Diabetes Therapy 15:2, pages 547-563.
Crossref
Cheng Cai Tang, Jean Lim, Li Shen Loo, Heike Jung, Manige Konig & Lai San Tham. (2023) Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide. The Journal of Clinical Pharmacology 64:2, pages 215-226.
Crossref
Peter Y.W. Chan, Aleksander P. Mika, J. Ryan Martin & Jacob M. Wilson. (2024) Glucagon-like Peptide-1 Agonists. JBJS Reviews 12:1.
Crossref
Daniel Burton, Stephanie Gysel & Ross T. Tsuyuki. (2023) Why we need to incorporate obesity medicine into community pharmacies. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 157:1, pages 3-6.
Crossref
John W. Ostrominski & Tiffany M. Powell-Wiley. (2023) Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease. Current Atherosclerosis Reports 26:1, pages 11-23.
Crossref
Kevin Yau, Ayodele Odutayo, Satya Dash & David Z.I. Cherney. (2023) Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. Canadian Journal of Cardiology 39:12, pages 1816-1838.
Crossref
Aditi R. Saxena, Juan P. Frias, Donal N. Gorman, Rene N. Lopez, Nabil Andrawis, Nikolaos Tsamandouras & Morris J. Birnbaum. (2023) Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes. Diabetes, Obesity and Metabolism 25:10, pages 2805-2814.
Crossref
Aleksandra Szczesnowicz, Anna Szeliga, Olga Niwczyk, Gregory Bala & Blazej Meczekalski. (2023) Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. Journal of Clinical Medicine 12:18, pages 5915.
Crossref
Rodolfo J Galindo, Jennifer M Trujillo, Cecilia C Low Wang & Rozalina G McCoy. (2023) Advances in the management of type 2 diabetes in adults. BMJ Medicine 2:1, pages e000372.
Crossref
Hanlin Han, Yixin Sun, Weixu Zhang, Zhenya Zhang & Tian Yuan. (2023) The Effect of Nanobubble Water Containing Cordyceps Extract and Withaferin A on Free Fatty Acid-Induced Lipid Accumulation in HepG2 Cells. Nanomaterials 13:15, pages 2265.
Crossref
Khalid M. Alhusayni, Abdulmajeed M. Aljuaid, Abdulaziz M. Alkhammash, Shahad A. Alzahrani, Abeer K. Alorabi, Yasmin B. Alotaibi, Nidaa T. Alhumaidi, Waad K. Alharbi, Ghaliah A. Harbi & Ibrahim Alzahrani. (2023) The Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonist Drugs: A Comprehensive Literature Review. Open Access Macedonian Journal of Medical Sciences 11:F, pages 286-292.
Crossref
Edward R. Sauter. (2023) Response letter. Surgery for Obesity and Related Diseases 19:8, pages 929.
Crossref
A. V. Vitebskaya & A. V. Popovich. (2023) Liraglutide in adolescents with simple obesity and gastrointestinal comorbidities: treatment experience. Obesity and metabolism 20:2, pages 124-130.
Crossref
Erin D. Michos, Francisco Lopez‐Jimenez & Martha Gulati. (2023) Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. Journal of the American Heart Association 12:11.
Crossref
Marlene Chakhtoura & Christos S. Mantzoros. (2023) Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy. Metabolism 142, pages 155531.
Crossref
Jessica Kearney & Luigi Gnudi. (2023) The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes. Pharmaceutics 15:5, pages 1343.
Crossref
Konstantinos Arvanitakis, Theocharis Koufakis, Djordje Popovic, Giuseppe Maltese, Omar Mustafa, Michael Doumas, Olga Giouleme, Kalliopi Kotsa & Georgios Germanidis. (2023) GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use. Current Obesity Reports 12:2, pages 61-74.
Crossref
Fatma Haddad, Ghadeer Dokmak, Maryam Bader & Rafik Karaman. (2023) A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life 13:4, pages 1012.
Crossref
Aaron King & Eden M. Miller. (2023) Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?. Clinical Diabetes 41:2, pages 226-238.
Crossref
Omar S. Alkhezi, Abdullah A. Alahmed, Osamah M. Alfayez, Osama A. Alzuman, Abdulaali R. Almutairi & Omar A. Almohammed. (2022) Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials. Obesity Reviews 24:3.
Crossref
Natasha Chidekel Bergmann, Melanie J. Davies, Ildiko Lingvay & Filip K. Knop. (2022) Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism 25:1, pages 18-35.
Crossref
Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz & Miguel Ángel Rubio-Herrera. (2022) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine 12:1, pages 145.
Crossref
O. V. Vasyukova, P. L. Okorokov & O. B. Bezlepkina. (2022) Modern strategies for the treatment of childhood obesity. Problems of Endocrinology 68:6, pages 131-136.
Crossref
Shasta Tall Bull, Wesley Nuffer & Jennifer M. Trujillo. (2022) Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. Journal of Diabetes and its Complications 36:12, pages 108332.
Crossref
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green, Nisa M. Maruthur, Sylvia E. Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Tsvetalina Tankova, Apostolos Tsapas & John B. Buse. (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65:12, pages 1925-1966.
Crossref
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green, Nisa M. Maruthur, Sylvia E. Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Tsvetalina Tankova, Apostolos Tsapas & John B. Buse. (2022) Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45:11, pages 2753-2786.
Crossref
Belma Turan, Aysegul Durak, Yusuf Olgar & Erkan Tuncay. (2022) Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction. Molecular and Cellular Biochemistry 477:11, pages 2609-2625.
Crossref
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa & Georgios Germanidis. (2022) How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. Cancers 14:19, pages 4651.
Crossref
Meir Schechter, Matan Fischer & Ofri Mosenzon. (2022) Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide ‐1 receptor agonists: A narrative review and proposed clinical approach . Diabetes, Obesity and Metabolism 24:6, pages 969-982.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.